Investigating new inhibitors for immune response regulation
Macrocyclic Peptidyl Inhibitors of NEMO-IKK Interaction
['FUNDING_R01'] · OHIO STATE UNIVERSITY · NIH-10653996
This study is looking at new ways to create special proteins that can help control the immune system by blocking a specific interaction that leads to inflammation, which could lead to better treatments for people with inflammatory and autoimmune diseases.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OHIO STATE UNIVERSITY (nih funded) |
| Locations | 1 site (Columbus, UNITED STATES) |
| Trial ID | NIH-10653996 on ClinicalTrials.gov |
What this research studies
This research focuses on developing macrocyclic peptides that can inhibit the interaction between NEMO and IKK, which is crucial for regulating the immune response. By blocking this interaction, the researchers aim to control the activation of NF-κB, a key factor involved in many inflammatory and autoimmune diseases. The project involves optimizing a specific peptidyl inhibitor and characterizing its properties through various biochemical and structural methods. Patients may benefit from new treatments that could reduce inflammation and improve immune function.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from autoimmune diseases or chronic inflammatory conditions.
Not a fit: Patients with non-autoimmune related conditions or those not experiencing inflammation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies for patients with autoimmune diseases and inflammatory conditions.
How similar studies have performed: Previous research has shown promise in targeting NF-κB pathways, but this specific approach using macrocyclic peptides is relatively novel.
Where this research is happening
Columbus, UNITED STATES
- OHIO STATE UNIVERSITY — Columbus, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PEI, DEHUA — OHIO STATE UNIVERSITY
- Study coordinator: PEI, DEHUA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autoimmune Diseases, autoimmune disorder, autoimmunity disease